Education · Tier 2

· Last Reviewed May 12, 2026· PSI Editorial Board· Independent

What Should I Expect at a Peptide Consultation?

The honest map of what happens at a peptide therapy consultation across the eight-step framework from scheduling to follow-up care.

A peptide consultation follows an eight-step framework.

The framework spans scheduling through follow-up care.

The visit covers indication assessment, FDA-approved alternative consideration, and informed consent.

Patients should prepare medication lists, insurance details, and prior bloodwork records.

8 Steps

Consultation Framework

Scheduling through follow-up care across eight clinical and regulatory steps

AMA 1.1.5

Informed Consent

AMA Code of Medical Ethics 1.1.5 governs off-label and compounded informed consent

Baseline Labs

Bloodwork Standard

Baseline bloodwork ordering per FDA prescribing information for FDA-approved peptides

Specialty Match

Indication-Driven

Indication-driven specialty match shapes the clinical evaluation framework

Quick Answer

A peptide consultation follows an eight-step framework. The framework spans scheduling through follow-up care.

The first step is scheduling the appointment and verifying physician active state medical board licensure. For telehealth, verify the physician holds an active license in YOUR state of residence. The second step is pre-visit preparation. Bring current medication list, indication-specific symptom notes, prior bloodwork records, and insurance information.

The third step is the initial clinical assessment. The physician reviews medical history, current medications, indication context, and conducts physical examination for in-person visits. The fourth step is indication-specific evaluation with FDA-approved alternative consideration per AMA Code of Medical Ethics 1.1.5.

The fifth step is baseline bloodwork ordering per FDA prescribing information. The sixth step is AMA Code 1.1.5 informed consent discussion for off-label or compounded prescribing. The discussion documents risk-benefit assessment, alternatives considered, and patient understanding.

The seventh step is the prescription decision. For FDA-approved peptides like Semaglutide (Wegovy or Ozempic) or Tirzepatide (Zepbound or Mounjaro), the prescription routes through retail pharmacy with insurance prior authorization. For compounded prescribing, the physician verifies 503A or 503B pharmacy quality assurance.

The eighth step is follow-up planning. The physician establishes follow-up frequency, monitoring laboratory schedule, and ongoing dose titration framework per FDA prescribing information.

For specific guidance, see Finding a Peptide Doctor and How Physicians Recommend Peptides. Also see Do I Need a Doctor for Peptides and Compounded vs FDA-Approved Peptides.

The peptide consultation establishes the physician-patient relationship through individualized clinical evaluation. The first step is scheduling the appointment and verifying physician state medical board licensure. The second step is pre-visit preparation including medication lists and indication-specific symptom notes. The third step is the initial clinical assessment covering history and physical examination. The fourth step is indication-specific evaluation with FDA-approved alternative consideration. The fifth step is baseline bloodwork ordering per FDA prescribing information. The sixth step is AMA Code of Medical Ethics 1.1.5 informed consent discussion for off-label or compounded prescribing. The seventh step is the prescription decision with pharmacy verification. The eighth step is the follow-up plan and ongoing monitoring.

CONSULTATION FRAMEWORK

At a Glance: Peptide Consultation: What to Expect

Consultation Step	Subtitle	Animal Evidence	Human Evidence	What Happens
Step one: schedule appointment and verify state licensure	Pre-visit administrative and regulatory verification	—	Strong	Verify physician active state medical license in your state of residence and confirm telehealth or in-person pathway
Step two: pre-visit preparation with medication and history records	Pre-visit clinical and administrative preparation	—	Strong	Bring current medication list, indication-specific symptom notes, prior bloodwork records, and insurance information
Step three: initial clinical assessment with history and physical examination	Comprehensive baseline clinical evaluation	—	Strong	Physician reviews medical history, current medications, indication context, and conducts physical examination if in-person
Step four: indication-specific evaluation with FDA-approved alternative consideration	Indication-driven clinical decision framework	—	Strong	Physician evaluates FDA-approved alternatives like Wegovy or Ozempic before compounded pathway consideration per AMA Code 1.1.5
Step five: baseline bloodwork ordering per FDA prescribing information	Baseline laboratory testing for monitoring framework	—	Strong	Physician orders baseline bloodwork per FDA prescribing information for the specific peptide and indication
Step six: AMA Code 1.1.5 informed consent discussion	Risk-benefit and alternative discussion documentation	—	Strong	For off-label or compounded prescribing, physician documents risk-benefit assessment, alternatives considered, and patient understanding
Step seven: prescription decision and pharmacy verification	Prescription routing through FDA-approved or compounded pathway	—	Strong	Physician selects FDA-approved or compounded pathway with documented pharmacy verification for compounded prescribing
Step eight: follow-up plan and ongoing monitoring	Continuity of care framework	—	Strong	Physician establishes follow-up frequency, monitoring labs, and ongoing dose titration framework per FDA prescribing information

Six Things You Need to Know About a Peptide Consultation

This page covers the eight-step framework for a peptide therapy consultation. The framework spans six sections. Section one covers pre-visit preparation. Section two covers the initial clinical assessment. Section three details indication-specific evaluation. Section four addresses baseline bloodwork and AMA Code 1.1.5 informed consent. Section five covers prescription decision and pharmacy verification. Section six addresses follow-up planning and ongoing monitoring.

Pre-Visit Preparation Includes Medication List, History Records, and Insurance Details

Pre-visit preparation for a peptide consultation includes current medication list, indication-specific symptom notes, prior bloodwork records, insurance information, and physician state medical board licensure verification.

The first phase of a peptide consultation is pre-visit preparation. The current medication list should include all prescription medications, over-the-counter medications, and supplements with dosing details. Indication-specific symptom notes should cover the clinical context that brought the patient to the consultation including symptom duration, severity, prior interventions, and current quality of life impact. Prior bloodwork records from the past twelve months should be available for the physician to review. Insurance information including plan details, prior authorization history for similar medications, and coverage verification for the specific peptide under consideration is helpful. Physician state medical board licensure verification is the foundational regulatory step. Patients can verify through the state board portal that the physician holds an active and unrestricted medical license in the state where they practice. For telehealth consultation, verify the physician holds an active license in the patient's state of residence. The pre-visit preparation phase strengthens the clinical conversation during the actual consultation by ensuring the physician has the context needed for individualized evaluation. Patients should consult primary care or specialty practice about specific pre-visit preparation guidance for their clinical context.

Initial Clinical Assessment Covers History, Indication Context, and Physical Examination

The initial clinical assessment covers medical history review, current medication review, indication-specific symptom assessment, physical examination (for in-person visits), and baseline measurements including vital signs and body composition for weight management indications.

The initial clinical assessment is the foundation of the peptide consultation. The medical history review covers past medical history, surgical history, family history, social history, allergies, and prior medication response patterns. The current medication review identifies potential drug interactions with the peptide under consideration. The indication-specific symptom assessment evaluates the clinical context for peptide therapy. For weight management indications, the assessment includes BMI calculation, weight history, prior weight management interventions, and metabolic comorbidities. For type 2 diabetes indications, the assessment includes hemoglobin A1c history, current diabetes management, cardiovascular risk factors, and CGM data if available. For osteoporosis indications, the assessment includes DEXA bone density results, fracture history, FRAX score, and prior osteoporosis therapy. For growth hormone deficiency indications, the assessment includes symptoms suggesting adult-onset GHD, IGF-1 levels if available, and prior pituitary imaging if relevant. The physical examination (for in-person visits) covers vital signs, body composition assessment, and indication-specific physical findings. The initial clinical assessment establishes the baseline clinical context for the indication-specific evaluation that follows.

Indication-Specific Evaluation Includes FDA-Approved Alternative Consideration

Indication-specific evaluation under AMA Code of Medical Ethics 1.1.5 requires consideration of FDA-approved alternatives before any off-label or compounded peptide prescribing decision. The framework is structural and is documented in the medical record.

Indication-specific evaluation follows the initial clinical assessment. The evaluation framework matches the patient's indication with the appropriate peptide therapy decision. For weight management, the evaluation considers FDA-approved Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3.0 mg), and Zepbound (tirzepatide 5/10/15 mg) per the FDA prescribing information and the AACE 2022 weight management framework. For type 2 diabetes, the evaluation considers FDA-approved Ozempic, Victoza, Trulicity, Mounjaro per the ADA 2024 Standards of Care framework with attention to cardiovascular outcomes data including SELECT 2023 (Lincoff et al. NEJM) and SUSTAIN-6 (Marso et al. NEJM 2016). For high fracture risk osteoporosis, the evaluation considers FDA-approved Forteo, Tymlos, and Evenity per AACE/ACE 2020 and Endocrine Society 2019 CPGs with attention to the Evenity cardiovascular boxed warning. For adult-onset growth hormone deficiency, the evaluation considers FDA-approved Sermorelin, Tesamorelin, or somatropin per AACE 2019 GHD CPG with insulin tolerance test or glucagon stimulation test confirmation. The AMA Code of Medical Ethics 1.1.5 framework requires consideration of FDA-approved alternatives before any off-label or compounded peptide prescribing decision. The framework is documented in the medical record including the risk-benefit assessment and alternatives considered.

Baseline Bloodwork Ordering Follows FDA Prescribing Information

Baseline bloodwork ordering for peptide therapy follows FDA prescribing information for the specific peptide and indication. Common baseline panels include comprehensive metabolic panel, lipid panel, hemoglobin A1c, and indication-specific markers.

Baseline bloodwork is the laboratory foundation for peptide therapy monitoring. For GLP-1 receptor agonist therapy (Wegovy, Ozempic, Zepbound, Mounjaro), baseline labs typically include comprehensive metabolic panel (CMP) covering kidney function and liver function, lipid panel, hemoglobin A1c for both diabetes and pre-diabetes screening, fasting glucose, and indication-specific markers. For osteoporosis peptide therapy (Forteo, Tymlos, Evenity), baseline labs include calcium, 25-OH vitamin D, parathyroid hormone, CMP for kidney function, and bone turnover markers per AACE/ACE 2020 and Endocrine Society 2019 CPGs. For GHD evaluation, baseline labs include IGF-1, insulin tolerance test or glucagon stimulation test results, and pituitary hormone panel per AACE 2019 GHD CPG. For HIV-associated lipodystrophy (Tesamorelin), baseline labs include lipid panel, glucose, IGF-1, and HIV viral load per FDA prescribing information. Baseline bloodwork ordering can occur in-office for in-person consultations or through external laboratory networks (Quest Diagnostics, LabCorp) for telehealth consultations. The bloodwork results inform the prescription decision and establish the baseline for ongoing monitoring per FDA prescribing information.

AMA Code 1.1.5 Informed Consent Discussion Documents the Prescribing Framework

AMA Code of Medical Ethics 1.1.5 informed consent discussion is required for off-label use of FDA-approved peptides and for compounded peptide prescribing. The discussion documents risk-benefit assessment, alternatives considered, and patient understanding.

AMA Code of Medical Ethics 1.1.5 governs off-label and investigational use of pharmaceuticals. AMA Code 2.1.1 establishes the broader informed consent framework. For peptide therapy, informed consent documentation is required in three scenarios. The first is off-label use of FDA-approved peptides (for example, using Ozempic for weight management when prescribed before Wegovy was available, or using Tesamorelin off-label for non-HIV indications). The second is compounded peptide prescribing through 503A or 503B pharmacies including documented physician verification of pharmacy quality assurance. The third is investigational or experimental peptide use through clinical trials or expanded access programs. The informed consent discussion covers risk-benefit assessment for the specific patient context, alternatives considered including FDA-approved options, expected timeline and outcomes, monitoring requirements, adverse event reporting, and patient understanding of the decision. The discussion is documented in the medical record. Patients can request copies of informed consent documentation. The framework supports patient autonomy and shared decision-making while protecting both patient and physician within the validated clinical practice framework.

Prescription Decision Includes Pharmacy Verification for Compounded Pathways

The prescription decision routes the patient through FDA-approved pharmacy pathway (retail pharmacy with insurance prior authorization) or compounded pathway (503A state pharmacy or 503B FDA-registered outsourcing facility) with documented physician pharmacy verification.

The prescription decision is the action point of the consultation. For FDA-approved peptide therapy, the prescription routes through standard retail pharmacy with insurance prior authorization. The prior authorization process typically requires documentation of indication, prior interventions, BMI threshold (for weight management), or hemoglobin A1c threshold (for type 2 diabetes). Most FDA-approved peptide indications have established prior authorization frameworks with major insurance plans. For compounded peptide prescribing, the prescription routes through a 503A pharmacy (state pharmacy board licensed) or 503B outsourcing facility (FDA registered). The physician should provide documented verification of pharmacy quality assurance including state license verification (for 503A) or FDA registration verification (for 503B), PCAB accreditation status, USP Chapter 797 sterile compounding compliance, USP Chapter 800 hazardous drug handling compliance, third-party purity and potency testing practices, and adverse event reporting protocols. Patients should request the specific pharmacy name and verification documentation. The compounded prescription is typically billed cash since most insurance plans do not cover compounded peptide preparations. Patients should consult primary care or specialty practice about insurance coverage and pharmacy verification specific to their prescription decision.

Pre-visit preparation: medication list, history records, and licensure verification

How patients should prepare before the peptide consultation appointment

Pre-visit preparation strengthens the clinical conversation during the actual consultation by ensuring the physician has the context needed for individualized evaluation. The current medication list should include all prescription medications, over-the-counter medications, and supplements with dosing details. Drug interactions with the peptide under consideration are part of the indication-specific evaluation framework.

Indication-specific symptom notes should cover the clinical context that brought the patient to the consultation. For weight management indications, document weight history, BMI trajectory, prior weight management interventions, and metabolic comorbidities. For type 2 diabetes indications, document hemoglobin A1c history, current diabetes management, cardiovascular risk factors, and continuous glucose monitor data if available. For osteoporosis indications, document DEXA bone density results, fracture history, FRAX score, and prior osteoporosis therapy.

Prior bloodwork records from the past twelve months should be available for the physician to review. Insurance information including plan details and prior authorization history is helpful for FDA-approved peptide prescribing. Physician state medical board licensure verification is the foundational regulatory step. For telehealth consultations, verify the physician holds an active medical license in the patient's state of residence per the patient-state-driven licensing requirement.

Initial clinical assessment: history, indication context, and physical examination

What the physician evaluates during the comprehensive initial visit assessment

The indication-specific symptom assessment evaluates the clinical context for peptide therapy. For weight management indications, the assessment includes BMI calculation, weight history, prior weight management interventions, and metabolic comorbidities. For type 2 diabetes, the assessment includes hemoglobin A1c history, current diabetes management, and cardiovascular risk factors per the ADA 2024 Standards of Care framework. For osteoporosis, the assessment includes DEXA bone density results, fracture history, and FRAX score per AACE/ACE 2020 and Endocrine Society 2019 CPGs.

The physical examination (for in-person visits) covers vital signs (blood pressure, heart rate, weight, height for BMI calculation), body composition assessment for weight management indications, musculoskeletal examination for sports medicine indications, and indication-specific physical findings. For telehealth consultations, the physical examination is limited but visual assessment, blood pressure self-measurement, and weight self-measurement can be incorporated.

Indication-specific evaluation with FDA-approved alternative consideration

How AMA Code 1.1.5 framework governs the prescribing decision

For weight management, the evaluation considers FDA-approved Wegovy (semaglutide 2.4 mg, NDA 215256), Saxenda (liraglutide 3.0 mg), and Zepbound (tirzepatide, NDA 217806) per FDA prescribing information and the AACE 2022 weight management framework. SURMOUNT-1 2022 (Jastreboff et al. NEJM) demonstrated approximately 21 percent weight reduction with tirzepatide. SELECT 2023 (Lincoff et al. NEJM) demonstrated approximately 20 percent MACE reduction with semaglutide in obesity without diabetes.

For type 2 diabetes, the evaluation considers FDA-approved Ozempic (semaglutide, NDA 209637), Victoza, Trulicity, and Mounjaro (tirzepatide, NDA 215866) per the ADA 2024 Standards of Care framework with attention to cardiovascular outcomes data from SUSTAIN-6 (Marso et al. NEJM 2016). For high fracture risk osteoporosis, the evaluation considers FDA-approved Forteo (teriparatide, NDA 021318), Tymlos (abaloparatide), and Evenity (romosozumab, NDA 761062 with cardiovascular boxed warning) per AACE/ACE 2020 (Camacho et al.) and Endocrine Society 2019 (Eastell et al.) CPGs.

AMA Code of Medical Ethics 1.1.5 framework requires consideration of FDA-approved alternatives before any off-label or compounded peptide prescribing decision. The framework is structural and is documented in the medical record. The documentation includes the risk-benefit assessment for the specific patient context, alternatives considered, expected timeline and outcomes, and the prescribing rationale.

Bloodwork, informed consent, prescription decision, and follow-up planning

The final phases of the consultation including prescription routing and monitoring framework

Baseline bloodwork ordering follows FDA prescribing information for the specific peptide and indication. For GLP-1 receptor agonist therapy, baseline labs include comprehensive metabolic panel, lipid panel, hemoglobin A1c, and fasting glucose. For osteoporosis peptide therapy, baseline labs include calcium, 25-OH vitamin D, parathyroid hormone, and bone turnover markers. For GHD evaluation, baseline labs include IGF-1 and dynamic testing results per AACE 2019 GHD CPG.

AMA Code of Medical Ethics 1.1.5 informed consent discussion is required for off-label use of FDA-approved peptides and compounded peptide prescribing. The discussion documents risk-benefit assessment, alternatives considered, monitoring requirements, and patient understanding. AMA Code 2.1.1 establishes the broader informed consent framework. Patients can request copies of informed consent documentation.

The prescription decision routes through FDA-approved retail pharmacy with insurance prior authorization or compounded pathway with physician pharmacy verification. For compounded prescribing, the physician verifies 503A state pharmacy board license or 503B FDA registration, PCAB accreditation, USP Chapter 797 and 800 compliance, third-party testing practices, and adverse event reporting protocols. The follow-up plan establishes monthly to quarterly follow-up frequency, monitoring laboratory schedule, dose titration framework, and adverse event reporting plan.

Research Suggests

Direction

A peptide consultation follows an eight-step framework spanning scheduling through follow-up care under validated clinical practice frameworks.

The eight-step framework covers scheduling and physician licensure verification, pre-visit preparation, initial clinical assessment, indication-specific evaluation with FDA-approved alternative consideration, baseline bloodwork ordering, AMA Code of Medical Ethics 1.1.5 informed consent discussion, prescription decision with pharmacy verification, and follow-up planning. The framework operates under FDA prescribing information for FDA-approved peptides, AMA Code 1.1.5 and 2.1.1 for off-label and compounded prescribing, state medical board licensing, ABMS board certification standards, the FDA Compounding Quality Act for compounded pathways, ADA 2024 Standards of Care for type 2 diabetes, AACE/ACE 2020 and Endocrine Society 2019 CPGs for osteoporosis, and AACE 2019 GHD CPG for growth hormone deficiency.

Strongest evidence

FDA-approved peptide prescribing for FDA-approved indications has the strongest evidence base and regulatory framework foundation.

FDA-approved peptide therapy for FDA-approved indications operates within the strongest framework. Wegovy and Saxenda for chronic weight management. Ozempic and Victoza for type 2 diabetes. Zepbound and Mounjaro for chronic weight management and type 2 diabetes per ADA Standards of Care 2024. Forteo, Tymlos, and Evenity for high fracture risk osteoporosis per AACE/ACE 2020 and Endocrine Society 2019 CPGs. The prescription routes through retail pharmacy with insurance prior authorization. The consultation framework follows FDA prescribing information for each FDA-approved product.

Limitations

Off-label and compounded prescribing require additional AMA Code 1.1.5 documentation and pharmacy verification.

Off-label use of FDA-approved peptides requires documented AMA Code 1.1.5 informed consent including risk-benefit assessment and alternatives considered. Compounded peptide prescribing requires physician verification of pharmacy quality assurance including 503A state pharmacy board license or 503B FDA registration, PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing practices. Telehealth consultation operates under state medical board licensing for the patient's state of residence and DEA Ryan Haight Act framework for any controlled substance prescribing. Patients should consult primary care or specialty practice for individualized clinical context.

Assessment

The eight-step framework structures the consultation. The framework supports patient autonomy and shared decision-making.

PSI's reading: the eight-step peptide consultation framework establishes the physician-patient relationship through individualized clinical evaluation. The framework spans scheduling through follow-up care with each step contributing to the validated clinical practice foundation. The first step (scheduling and licensure verification) is administrative and regulatory. The second through fourth steps (pre-visit preparation, initial assessment, indication-specific evaluation) establish the clinical context. The fifth and sixth steps (baseline bloodwork and AMA Code 1.1.5 informed consent) establish the laboratory and consent foundation. The seventh step (prescription decision with pharmacy verification) is the action point. The eighth step (follow-up planning) establishes continuity of care. The framework applies to primary care and specialty practice across in-person, telehealth, and hybrid model contexts. The PSI physician directory provides verified physicians operating within this framework.

How to Approach Your Decision

Limitations and Caveats

The eight-step consultation framework spans scheduling through follow-up care. The first step is scheduling and physician licensure verification. The last step is follow-up planning and ongoing monitoring.
Pre-visit preparation includes medication list, symptom notes, prior bloodwork, and insurance information. Preparation strengthens the clinical conversation during the consultation.
The initial clinical assessment covers medical history, current medication review, indication context, and physical examination. The framework applies to primary care and specialty practice contexts.
Indication-specific evaluation requires FDA-approved alternative consideration per AMA Code of Medical Ethics 1.1.5. The framework is structural and documented in the medical record.
Baseline bloodwork ordering follows FDA prescribing information for the specific peptide and indication. Common baseline panels include CMP, lipid panel, hemoglobin A1c, and indication-specific markers.
AMA Code 1.1.5 informed consent discussion is required for off-label and compounded prescribing. The discussion documents risk-benefit assessment, alternatives considered, and patient understanding.
The prescription decision routes through FDA-approved retail pharmacy or compounded 503A/503B pathway with documented physician pharmacy verification. Verification includes state license or FDA registration, PCAB, USP, and third-party testing.
Follow-up planning establishes ongoing monitoring framework. Frequency typically ranges from monthly to quarterly depending on indication and FDA prescribing information.

What's Marketed vs What's Studied

7 common claims, corrected.

“A peptide consultation is a quick transactional visit focused on prescription.”

A quality peptide consultation follows an eight-step framework spanning scheduling through follow-up care. The framework includes individualized clinical evaluation, indication-specific assessment, FDA-approved alternative consideration per AMA Code 1.1.5, baseline bloodwork, informed consent documentation, and follow-up planning. Quick transactional visits that skip these elements operate outside validated clinical practice.

“I do not need to bring anything to a peptide consultation.”

Pre-visit preparation strengthens the clinical conversation significantly. Bring current medication list (prescription, OTC, supplements with dosing), indication-specific symptom notes, prior bloodwork from the past twelve months, insurance verification, and physician state medical board licensure verification. Preparation supports individualized evaluation and reduces visit time required for context gathering.

“The consultation will only discuss the specific peptide I want.”

The consultation will include indication-specific evaluation with FDA-approved alternative consideration per AMA Code of Medical Ethics 1.1.5. The physician will discuss FDA-approved options like Wegovy or Ozempic before any off-label or compounded peptide prescribing decision. This is structural and required for validated clinical practice.

“I do not need bloodwork before peptide therapy.”

Baseline bloodwork is the laboratory foundation for peptide therapy monitoring. FDA prescribing information for each FDA-approved peptide specifies baseline monitoring requirements. Common baseline panels include comprehensive metabolic panel, lipid panel, hemoglobin A1c, and indication-specific markers. Telehealth physicians can order bloodwork through external laboratory networks like Quest or LabCorp.

“Informed consent is just a quick signature on a form.”

AMA Code of Medical Ethics 1.1.5 informed consent documentation is a substantive process for off-label use of FDA-approved peptides and compounded peptide prescribing. The discussion documents risk-benefit assessment for your specific clinical context, alternatives considered (including FDA-approved options), expected timeline and outcomes, monitoring requirements, and patient understanding. Patients can request copies of the documentation.

“Compounded peptide prescriptions do not require pharmacy verification.”

Compounded peptide prescribing requires physician verification of pharmacy quality assurance. The verification includes 503A state pharmacy board license or 503B FDA registration, PCAB accreditation status, USP Chapter 797 sterile compounding compliance, USP Chapter 800 hazardous drug handling compliance, third-party purity and potency testing practices, and adverse event reporting protocols. Patients should request the specific pharmacy name and verification documentation.

“Follow-up after peptide consultation is optional.”

Follow-up care is structural to peptide therapy. FDA prescribing information specifies monitoring requirements including laboratory tests, dose titration timelines, and adverse event reporting protocols. Follow-up frequency typically ranges from monthly to quarterly depending on indication and peptide therapy stage. Telehealth supports follow-up care for established patient-physician relationships within indication.

Common Questions

How long does a peptide consultation take?

An initial peptide consultation typically takes 30 to 60 minutes covering the eight-step framework. The first visit covers medical history review, physical examination, indication-specific evaluation, FDA-approved alternative consideration, baseline bloodwork ordering, AMA Code 1.1.5 informed consent for off-label or compounded prescribing, prescription decision, and follow-up planning. Follow-up visits are typically shorter at 15 to 30 minutes for established patient relationships.

What should I bring to a peptide consultation?

Bring current medication list with dosing details, indication-specific symptom notes, prior bloodwork from the past twelve months, insurance information including any prior authorization history, list of questions about your specific clinical context, and physician state medical board licensure verification details. Pre-visit preparation strengthens the clinical conversation.

What happens at the first peptide consultation?

The first visit covers eight steps: scheduling verification and physician licensure check, pre-visit preparation review, initial clinical assessment with history and physical examination, indication-specific evaluation with FDA-approved alternative consideration, baseline bloodwork ordering, AMA Code 1.1.5 informed consent discussion for off-label or compounded prescribing, prescription decision with pharmacy verification, and follow-up plan establishment.

Will I get a prescription at the first visit?

You may receive a prescription at the first visit if the clinical evaluation supports FDA-approved peptide therapy for your indication and baseline bloodwork is satisfactory. For compounded peptide prescribing, additional pharmacy verification may extend the timeline. For complex indications requiring specialty referral, the prescription may follow specialty consultation. Quality clinical practice does not pre-commit to prescribing before clinical evaluation.

What bloodwork is required before peptide therapy?

Baseline bloodwork depends on the peptide and indication. For GLP-1 receptor agonist therapy, common baseline labs include comprehensive metabolic panel, lipid panel, hemoglobin A1c, and fasting glucose. For osteoporosis peptide therapy, baseline labs include calcium, 25-OH vitamin D, parathyroid hormone, and bone turnover markers. For GHD evaluation, baseline labs include IGF-1 and dynamic testing. See [Bloodwork Before Peptide Therapy](/education/bloodwork-before-peptide-therapy).

What is AMA Code 1.1.5 informed consent?

AMA Code of Medical Ethics 1.1.5 governs off-label and investigational use of pharmaceuticals. For peptide therapy, AMA Code 1.1.5 informed consent is required for off-label use of FDA-approved peptides and for compounded peptide prescribing. The discussion documents risk-benefit assessment, alternatives considered (including FDA-approved options), monitoring requirements, and patient understanding. AMA Code 2.1.1 establishes the broader informed consent framework.

Will my insurance cover the peptide consultation?

Insurance coverage for peptide consultation depends on the specialty, indication, and insurance plan. Primary care visits are generally covered with co-pays. Specialty visits may require referrals depending on plan. FDA-approved peptide prescriptions for FDA-approved indications generally have coverage with prior authorization. Compounded peptide prescriptions are typically not covered. Verify coverage with your insurance plan before the appointment.

Will the consultation discuss alternatives to peptide therapy?

Yes. AMA Code of Medical Ethics 1.1.5 requires consideration of FDA-approved alternatives before any off-label or compounded peptide prescribing decision. For weight management, the consultation considers Wegovy, Saxenda, Zepbound. For type 2 diabetes, Ozempic, Victoza, Mounjaro per ADA 2024 Standards of Care. For osteoporosis, Forteo, Tymlos, Evenity per AACE/ACE 2020 and Endocrine Society 2019 CPGs. The framework is documented in the medical record.

Can a telehealth peptide consultation cover everything?

Telehealth peptide consultation can cover most of the eight-step framework with specific limitations. Physical examination is limited but visual assessment, blood pressure self-measurement, and weight self-measurement can be incorporated. Bloodwork ordering goes through external laboratory networks like Quest or LabCorp. Initial controlled substance prescribing operates under DEA Ryan Haight Act requirements. See [Telehealth vs In-Person Peptide Prescriptions](/education/telehealth-vs-in-person-peptide-prescriptions).

How is follow-up care structured after the consultation?

Follow-up care typically follows monthly to quarterly cadence depending on indication and FDA prescribing information. For GLP-1 receptor agonist therapy, follow-up supports dose titration, side effect management, and weight or A1c monitoring. For osteoporosis peptide therapy, follow-up supports calcium and vitamin D monitoring plus bone turnover markers. Follow-up can occur in-person or through telehealth for established patient relationships.

What if the consultation reveals I am not a candidate for peptide therapy?

If indication-specific evaluation does not support peptide therapy, the consultation will discuss alternative interventions. For weight management, alternatives may include lifestyle interventions, bariatric surgery referral, or alternative pharmacotherapy. For type 2 diabetes, alternatives may include metformin, SGLT2 inhibitors, or insulin per ADA 2024 Standards of Care. Quality clinical practice provides individualized recommendations regardless of whether peptide therapy is appropriate.

How do I prepare for the AMA Code 1.1.5 informed consent discussion?

Prepare questions about the specific peptide under consideration: What are the FDA-approved alternatives? What is the evidence base? What are the known risks and side effects? What are the monitoring requirements? For compounded prescribing: Which specific pharmacy is used? What are the pharmacy verification practices? What is the cost? What is the adverse event reporting protocol? Patient understanding is documented as part of the consent process.

Can I ask for copies of consultation documentation?

Yes. Patients have the right to access their medical records including consultation documentation. Request copies of the medical history, physical examination findings, baseline bloodwork orders, AMA Code 1.1.5 informed consent documentation for off-label or compounded prescribing, prescription details, and follow-up plan. The documentation supports continuity of care across providers and patient understanding of the clinical decision.

What questions should I ask the physician during the consultation?

Key questions include: What is your experience with peptide therapy for my specific indication? Which FDA-approved alternatives apply to my context? What is the AMA Code 1.1.5 informed consent process? For compounded prescribing, which specific pharmacy will be used? What monitoring is required? What is the follow-up frequency? How do I report adverse events? What is the expected timeline for clinical response?

What should I do if the consultation feels rushed or transactional?

Quality clinical practice does not rush through individualized clinical evaluation. If the consultation feels rushed, request additional time for questions about indication-specific evaluation, FDA-approved alternative consideration, AMA Code 1.1.5 informed consent, and follow-up planning. If the practice does not accommodate substantive clinical conversation, that may signal a red flag. See [Red Flags in Peptide Prescribing](/education/red-flags-in-peptide-prescribing).

How does the consultation differ for FDA-approved versus compounded prescribing?

FDA-approved prescribing follows FDA prescribing information for the specific product with retail pharmacy routing and insurance prior authorization. Compounded prescribing requires additional AMA Code 1.1.5 informed consent documentation, physician verification of 503A or 503B pharmacy quality assurance (state license, FDA registration, PCAB, USP standards, third-party testing), and typically cash payment since insurance does not cover compounded preparations.

What happens if I have an adverse event after starting peptide therapy?

Contact your prescribing physician immediately for adverse event evaluation and management. The physician will document the adverse event, evaluate the clinical context, and modify therapy as appropriate. Serious adverse events should be reported to the FDA MedWatch program. For FDA-approved peptide adverse events, the FDA tracks safety signals through post-market surveillance. For compounded peptide adverse events, the 503A pharmacy or 503B outsourcing facility has reporting protocols per FDA Compounding Quality Act.

Where can I find a verified physician for peptide consultation?

The PSI physician directory provides verified physicians across major US cities (NY, Miami, LA, Dallas, Austin) including peptide therapy experience verification, state medical board license verification, ABMS board certification verification, and AMA Code 1.1.5 documentation practice verification. The directory is independent and applies the same five-gate standard across all listed physicians. See [Finding a Peptide Doctor](/education/finding-a-peptide-doctor) for the full physician selection framework.

Sourcing Checklist

Before scheduling, verify physician active state medical board license through the state board portal.
The state medical board portal confirms active and unrestricted license status. For telehealth, verify the physician holds an active license in YOUR state of residence per patient-state-driven licensing.
Verify ABMS board certification through certificationmatters.org before the appointment.
Board certification confirms accredited residency completion, specialty board examination passing, and continuing medical education compliance. For weight management, American Board of Obesity Medicine is one relevant subspecialty.
Prepare current medication list including prescription, OTC, and supplements with dosing.
The medication list supports drug interaction screening as part of the indication-specific evaluation framework. FDA prescribing information specifies contraindications and interaction warnings for each FDA-approved peptide.
Compile indication-specific symptom notes covering duration, severity, and prior interventions.
For weight management, document weight history, BMI trajectory, and prior interventions. For type 2 diabetes, document A1c history and current management. For osteoporosis, document DEXA results and fracture history.
Gather prior bloodwork records from the past twelve months for physician review.
Prior bloodwork supports trend analysis and reduces redundant baseline testing. Many baseline labs from primary care visits in the past year may not require repeat ordering depending on FDA prescribing information.
During the visit, expect indication-specific evaluation with FDA-approved alternative consideration.
AMA Code 1.1.5 framework requires consideration of FDA-approved alternatives before off-label or compounded prescribing. Quality practice documents the alternatives considered and rationale.
For off-label or compounded prescribing, expect AMA Code 1.1.5 informed consent documentation.
The discussion documents risk-benefit assessment, alternatives considered, monitoring requirements, and patient understanding. Patients can request copies of the documentation.
For compounded prescribing, expect physician pharmacy verification documentation.
Verification includes 503A state pharmacy board license or 503B FDA registration, PCAB accreditation, USP Chapter 797 and 800 compliance, third-party testing, and adverse event reporting protocols.
Establish follow-up plan including frequency, monitoring labs, and adverse event reporting.
Follow-up frequency typically ranges from monthly to quarterly depending on indication and FDA prescribing information. Follow-up can be in-person, telehealth, or hybrid model.

Regulatory Context

The regulatory framework governing peptide consultation practice evolves continuously. FDA prescribing information for FDA-approved peptides updates with each labeling cycle including new indications, contraindications, and adverse event profile updates. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks for off-label and informed consent remain foundational with periodic refinements. ADA Standards of Care updates annually for type 2 diabetes peptide therapy. AACE/ACE and Endocrine Society guidelines for osteoporosis update periodically. State medical board telehealth regulations evolve with state-specific changes. The DEA Ryan Haight Act controlled substance framework has been modified by COVID-19 era flexibilities and DEA proposed permanent rules. The FDA Compounding Quality Act enforcement landscape evolves with state pharmacy board oversight cycles and 503B outsourcing facility inspection cadences. PSI tracks regulatory changes and updates this page per the Editorial Standards review cadence. Discuss with primary care or specialty practice for current consultation framework applicable to your specific clinical context.

Comparison

Step	Phase	Duration	Primary Output
Step 1: Schedule and verify licensure	Pre-Visit	5-10 min	Confirmed appointment with verified physician licensure
Step 2: Pre-visit preparation	Pre-Visit	15-30 min	Medication list, symptom notes, bloodwork records, insurance info
Step 3: Initial clinical assessment	During Visit	10-15 min	Medical history, medication review, indication context, physical exam
Step 4: Indication-specific evaluation	During Visit	10-15 min	FDA-approved alternative consideration, indication match assessment
Step 5: Baseline bloodwork ordering	During Visit	5-10 min	Laboratory orders per FDA prescribing information
Step 6: AMA Code 1.1.5 informed consent	During Visit	10-15 min	Documented risk-benefit, alternatives, patient understanding
Step 7: Prescription decision and pharmacy verification	During Visit	5-10 min	Prescription routed with pharmacy verification documented
Step 8: Follow-up planning	Post-Visit	5-10 min	Follow-up frequency, monitoring labs, adverse event protocol

Who This Applies To

· Adult preparing for first peptide therapy consultation and reviewing the eight-step framework.
· Adult gathering medication list, indication-specific symptom notes, and prior bloodwork before consultation.
· Adult verifying physician state medical board license and ABMS board certification before scheduling.
· Adult expecting indication-specific evaluation with FDA-approved alternative consideration during the visit.
· Adult preparing for AMA Code of Medical Ethics 1.1.5 informed consent discussion for off-label or compounded prescribing.
· Adult considering compounded peptide pathway and expecting physician pharmacy verification documentation.
· Adult preparing for baseline bloodwork ordering per FDA prescribing information for the specific peptide.
· Adult evaluating prescription decision routing including FDA-approved retail pharmacy or compounded 503A/503B pathway.
· Adult preparing follow-up plan including frequency, monitoring labs, and adverse event reporting protocols.
· Patient seeking documentation copies including AMA Code 1.1.5 informed consent and prescription details.

Verdict

A peptide consultation follows an eight-step framework spanning scheduling through follow-up care. The first step is scheduling the appointment and verifying physician state medical board licensure. The second step is pre-visit preparation including medication list and history records. The third step is the initial clinical assessment with medical history and physical examination. The fourth step is indication-specific evaluation with FDA-approved alternative consideration per AMA Code of Medical Ethics 1.1.5. The fifth step is baseline bloodwork ordering per FDA prescribing information. The sixth step is AMA Code 1.1.5 informed consent discussion for off-label or compounded prescribing. The seventh step is the prescription decision with pharmacy verification. The eighth step is the follow-up plan and ongoing monitoring. Quality clinical practice does not skip these steps. The framework applies across primary care, specialty practice, in-person, telehealth, and hybrid model contexts. The PSI physician directory provides verified physicians operating within this framework. Patients should consult primary care or specialty practice for individualized clinical context.

In Plain Terms

A peptide consultation follows eight steps. The first step is scheduling and making sure the doctor has a license in your state. The second step is getting ready before the visit. Bring your medication list, symptoms notes, prior bloodwork, and insurance info. The third step is the medical exam where the doctor reviews your history. The fourth step is looking at FDA-approved options first. The fifth step is ordering baseline bloodwork. The sixth step is the informed consent talk about risks and alternatives. The seventh step is the prescription. The eighth step is the follow-up plan. The whole thing usually takes 30 to 60 minutes for the first visit. Follow-ups are shorter. Always come prepared and ask questions.

Here is what to expect at a peptide consultation. The first visit usually takes 30 to 60 minutes. The doctor will go through eight steps. First, schedule and verify the doctor has a license in your state. Second, prepare by bringing your medications, symptoms, bloodwork, and insurance. Third, the doctor takes your history and examines you. Fourth, the doctor talks about FDA-approved options like Wegovy or Ozempic before any compounded options. Fifth, the doctor orders baseline bloodwork. Sixth, you discuss risks and benefits and sign informed consent. Seventh, the doctor writes the prescription. Eighth, you make a follow-up plan. Bring questions and request copies of documentation if you want them.

For any peptide consultation, physician selection through state medical board license verification, ABMS board certification, peptide experience verification, and AMA Code 1.1.5 framework adherence is the legal and clinical gate. PSI maintains a vetted directory of practitioners operating within validated clinical practice frameworks including primary care, telehealth, endocrinology, weight medicine, rheumatology, and other specialties.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Adult preparing for first peptide therapy consultation with comprehensive eight-step framework awareness
· Adult gathering pre-visit preparation materials including medication list and prior bloodwork records
· Adult expecting indication-specific evaluation with FDA-approved alternative consideration during visit
· Adult preparing for AMA Code 1.1.5 informed consent discussion for off-label or compounded prescribing
· Adult considering baseline bloodwork orders per FDA prescribing information for specific indication
· Adult evaluating compounded peptide pathway with expected physician pharmacy verification documentation
· Adult planning follow-up frequency including monthly to quarterly cadence per FDA prescribing information
· Adult considering telehealth consultation with patient-state-driven physician licensing requirements
· Adult preparing questions about FDA-approved alternatives, evidence base, and monitoring requirements
· Patient requesting documentation copies including informed consent and prescription details

Important Context

This page is educational and does not constitute medical advice. The information presented reflects FDA prescribing information for FDA-approved peptides, AMA Code of Medical Ethics 1.1.5 and 2.1.1, ADA 2024 Standards of Care, AACE/ACE and Endocrine Society guidelines, the FDA Compounding Quality Act of 2013, USP Chapter 797 and 800 standards, state medical board licensing frameworks, and the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 as referenced.

Your physician will conduct an individualized clinical evaluation considering your specific clinical context, indication match, current medications, prior interventions, insurance coverage, FDA-approved alternatives, and personal preferences when developing your peptide therapy plan. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination strengthens complex decisions across primary care and specialty practice.

Educational content only. Discuss with your physician about specific consultation framework applicable to your clinical context. Physician vetting should include state medical board license verification, ABMS board certification status, peptide therapy experience verification, and AMA Code 1.1.5 informed consent documentation practices. For compounded peptide pathways, verify pharmacy quality assurance including 503A state license, 503B FDA registration, PCAB accreditation, and USP Chapter 797 and 800 compliance.

Sources and Citations

[1] FDA Prescribing Information: Wegovy (semaglutide) injection 2.4 mg · 2024 · FDA NDA 215256 · Source
[2] FDA Prescribing Information: Ozempic (semaglutide) injection · 2024 · FDA NDA 209637 · Source
[3] FDA Prescribing Information: Zepbound (tirzepatide) injection · 2024 · FDA NDA 217806 · Source
[4] FDA Prescribing Information: Mounjaro (tirzepatide) injection · 2024 · FDA NDA 215866 · Source
[5] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[6] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[7] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[8] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine · 2022 · DOI
[9] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine · 2016 · DOI
[10] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[11] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
[12] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[13] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update · Endocrine Practice · 2020 · DOI
[14] Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline · Journal of Clinical Endocrinology and Metabolism · 2019 · DOI
[15] AACE Adult Growth Hormone Deficiency Clinical Practice Guidelines for Diagnosis and Treatment · Endocrine Practice · 2019
[16] FDA Compounding Quality Act of 2013: 503A pharmacy and 503B outsourcing facility framework · US Food and Drug Administration · 2013 · Source
[17] DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008: Telehealth controlled substance prescribing framework · US Drug Enforcement Administration · 2008 · Source
[18] American Board of Medical Specialties: Board certification framework and verification through certificationmatters.org · American Board of Medical Specialties · 2024 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.